211 related articles for article (PubMed ID: 29997033)
1. [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
Michel C; Vordos D; Dumont C; Basset V; Meyer F; Gaudez F; Meria P; Cortesse A; Mongiat-Artus P; de la Taille A; Culine S; Desgrandchamps F; Masson-Lecomte A
Prog Urol; 2018 Sep; 28(10):495-501. PubMed ID: 29997033
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
5. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
[TBL] [Abstract][Full Text] [Related]
6. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
[TBL] [Abstract][Full Text] [Related]
8. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
9. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y
Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer.
Stevenson SM; Danzig MR; Ghandour RA; Deibert CM; Decastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2014 Nov; 32(8):1172-7. PubMed ID: 24998787
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
Okabe K; Shindo T; Maehana T; Nishiyama N; Hashimoto K; Itoh N; Takahashi A; Taguchi K; Tachiki H; Tanaka T; Masumori N
Jpn J Clin Oncol; 2018 Oct; 48(10):934-941. PubMed ID: 30169681
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy.
Arora A; Zugail AS; Pugliesi F; Cathelineau X; Macek P; Barbé Y; Karnes RJ; Ahmed M; Di Trapani E; Soria F; Alvarez-Maestro M; Montorsi F; Briganti A; Necchi A; Pradere B; D'Andrea D; Krajewski W; Roumiguié M; Bajeot AS; Hurle R; Contieri R; Carando R; Teoh JY; Roupret M; Benamran D; Ploussard G; Mir MC; Sanchez-Salas R; Moschini M
World J Urol; 2022 Jul; 40(7):1697-1705. PubMed ID: 35488914
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
15. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
17. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
18. Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy.
Milenkovic U; Akand M; Moris L; Demaegd L; Muilwijk T; Bekhuis Y; Laenen A; Van Cleynenbreugel B; Everaerts W; Van Poppel H; Dumez H; Albersen M; Joniau S
World J Urol; 2019 Sep; 37(9):1857-1866. PubMed ID: 30519746
[TBL] [Abstract][Full Text] [Related]
19. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
